RVU — Ryvu Therapeutics SA Cashflow Statement
0.000.00%
Last trade - 00:00
- PLN1.14bn
- PLN915.91m
- PLN46.86m
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 286 | -31.7 | -79.1 | -83.8 | -92.1 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -331 | -5.8 | 22.5 | 31.4 | 10.9 |
Discontinued Operations | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 20.2 | 13.6 | -9.22 | 61.2 | -14.3 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -17.4 | -10.6 | -58.9 | 21.3 | -84.5 |
Capital Expenditures | -24 | -34.2 | -12 | -9.29 | -201 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 21.4 | -21.8 | 20 | 9.98 | 5.65 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.6 | -55.9 | 8.05 | 0.69 | -196 |
Financing Cash Flow Items | -0.218 | -8.44 | 0.821 | 0.057 | 250 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2.75 | 131 | -2.15 | -2.46 | 241 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -22.8 | 64.1 | -53 | 18.7 | -44 |